{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T21:25:09Z","timestamp":1787865909744,"version":"build-2784847793"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1053\/j.semnuclmed.2025.11.014","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T20:22:05Z","timestamp":1765657325000},"page":"31-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Response assessment in advanced differentiated thyroid cancer"],"prefix":"10.1053","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1512-7480","authenticated-orcid":false,"given":"Savvas","family":"Frangos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Giannoula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Iakovou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1053\/j.semnuclmed.2025.11.014_bib0001","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.3390\/ijms26115173","article-title":"Thyroid cancer: epidemiology, classification, risk factors, diagnostic and prognostic markers, and current treatment strategies","volume":"26","author":"Forma","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.014_bib0002","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12020-025-04228-5","article-title":"Predictors of response to lenvatinib in advanced differentiated thyroid cancer: focus on the CONUT score","volume":"89","author":"Talpacci","year":"2025","journal-title":"Endocrine"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.11.014_bib0003","first-page":"121","article-title":"Real-world applicability of differentiated thyroid cancer guidelines","volume":"27","author":"Giannoula","year":"2024","journal-title":"Hell J Nucl Med"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.11.014_bib0004","first-page":"927","article-title":"SNMMI procedure Standard\/EANM practice guideline for nuclear medicine evaluation and therapy of differentiated thyroid cancer: abbreviated version","volume":"63","author":"Avram","year":"2022","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.11.014_bib0005","first-page":"3654","article-title":"SNMMI\/EANM practice guideline vs. ETA Consensus statement: differences and similarities in approaching differentiated thyroid cancer management \u2014 The EANM perspective","volume":"49","author":"Petranovi\u0107 Ov\u010dari\u010dek","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.11.014_bib0006","first-page":"121","article-title":"Real-world applicability of differentiated thyroid cancer guidelines","volume":"27","author":"Giannoula","year":"2024","journal-title":"Hell J Nucl Med"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.11.014_bib0007","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.3390\/jcm9092708","article-title":"Dynamic risk stratification for predicting treatment response in differentiated thyroid cancer","volume":"9","author":"Giannoula","year":"2020","journal-title":"J Clin Med"},{"key":"10.1053\/j.semnuclmed.2025.11.014_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.954759","article-title":"Advanced differentiated thyroid cancer: A complex condition needing a tailored approach","volume":"12","author":"Bulfamante","year":"2022","journal-title":"Front Oncol"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.11.014_bib0009","first-page":"1347","article-title":"2016 American Thyroid Association Guidelines for management of patients with differentiated Thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"10.1053\/j.semnuclmed.2025.11.014_bib0010","article-title":"Management of advanced thyroid cancer: overview, advances, and opportunities","volume":"43","author":"Agosto Salgado","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.014_bib0011","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/hed.27025","article-title":"American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: defining advanced thyroid cancer and its targeted treatment","volume":"44","author":"Shonka","year":"2022","journal-title":"Head Neck"},{"key":"10.1053\/j.semnuclmed.2025.11.014_bib0012","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/S0140-6736(16)30172-6","article-title":"Thyroid cancer","volume":"388","author":"Cabanillas","year":"2016","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2025.11.014_bib0013","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc3431","article-title":"Molecular pathogenesis and mechanisms of thyroid cancer","volume":"13","author":"Xing","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.014_bib0014","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ando.2022.10.014","article-title":"Prognostic value of postoperative stimulated thyroglobulin in differentiated thyroid cancer","volume":"84","author":"Elmaraghi","year":"2023","journal-title":"Ann Endocrinol (Paris)"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.014_bib0015","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s12020-022-03021-y","article-title":"Value of stimulated pre-ablation thyroglobulin as a prognostic marker in patients with differentiated thyroid carcinoma treated with radioiodine","volume":"76","author":"N\u00f3brega","year":"2022","journal-title":"Endocrine"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.11.014_bib0016","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1089\/thy.2010.0355","article-title":"Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy","volume":"21","author":"Miyauchi","year":"2011","journal-title":"Thyroid"},{"key":"10.1053\/j.semnuclmed.2025.11.014_bib0017","doi-asserted-by":"crossref","unstructured":"Giovanella L, Garo ML, Albano D, et al. The role of thyroglobulin doubling time in differentiated thyroid cancer: a meta-analysis. Endocr Connect. 2022 Apr 15;11(4):e210648. doi: 10.1530\/EC-21-0648. PMID: 35245206; PMCID: PMC9066573.","DOI":"10.1530\/EC-21-0648"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.014_bib0018","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/07435800.2016.1173056","article-title":"Thyroglobulin levels and thyroglobulin\/thyrotropin ratio could predict the success of the ablative\/therapeutic 131I in the differentiated thyroid cancers","volume":"42","author":"Trevizam","year":"2017","journal-title":"Endocr Res"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.11.014_bib0019","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/RLU.0b013e3182291c65","article-title":"Predictive value of preablation stimulated thyroglobulin and thyroglobulin\/thyroid-stimulating hormone ratio in differentiated thyroid cancer","volume":"36","author":"Lin","year":"2011","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.014_bib0020","series-title":"Integrated Diagnostics and Theranostics of Thyroid Diseases","first-page":"569","article-title":"Biomarkers and molecular imaging in postoperative DTC management","author":"Albano","year":"2023"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.11.014_bib0021","first-page":"657","article-title":"Algeciras-Schimnich A. Usefulness of thyroglobulin and thyroglobulin antibody assays in the monitoring of differentiated thyroid carcinoma","volume":"38","author":"Netzel","year":"2018","journal-title":"Clin Lab Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.11.014_bib0022","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.beem.2013.07.003","article-title":"Thyroglobulin antibody (TgAb) methods\u2014Strengths, pitfalls, and clinical utility for monitoring thyroglobulin autoantibody-positive patients with differentiated thyroid carcinoma","volume":"27","author":"Spencer","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.11.014_bib0023","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1089\/thy.2012.0606","article-title":"Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement","volume":"23","author":"Verburg","year":"2013","journal-title":"Thyroid"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.11.014_bib0024","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1586\/eem.12.36","article-title":"Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions","volume":"7","author":"Pacini","year":"2012","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.11.014_bib0025","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40618-016-0578-6","article-title":"Relationship between circulating anti-thyroglobulin antibodies (TgAb) and tumor metabolism in patients with differentiated thyroid cancer (DTC): prognostic implications","volume":"40","author":"Morbelli","year":"2017","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.014_bib0026","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc3431","article-title":"Molecular pathogenesis and mechanisms of thyroid cancer","volume":"13","author":"Xing","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.11.014_bib0027","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/jamaoncol.2016.3288","article-title":"Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer Mortality","volume":"3","author":"Liu","year":"2017","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.11.014_bib0028","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrendo.2011.142","article-title":"Molecular genetics and diagnosis of thyroid cancer","volume":"7","author":"Nikiforov","year":"2011","journal-title":"Nat Rev Endocrinol"},{"issue":"9940","key":"10.1053\/j.semnuclmed.2025.11.014_bib0029","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine\u2013refractory, locally advanced or metastatic differentiated thyroid cancer: a randomized, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.11.014_bib0030","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.11.014_bib0031","first-page":"881","article-title":"Selective RET kinase inhibition for patients with RET-altered cancers","volume":"384","author":"Subbiah","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.11.014_bib0032","first-page":"177","article-title":"Effect of lenvatinib on response assessment by biochemical and imaging biomarkers in RAIR-DTC","volume":"30","author":"Brose","year":"2020","journal-title":"Thyroid"},{"issue":"19","key":"10.1053\/j.semnuclmed.2025.11.014_bib0033","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3390\/diagnostics15192493","article-title":"Molecular diagnostics and personalized therapeutics in differentiated thyroid carcinoma: A clinically oriented review","volume":"15","author":"Coca-Pelaz","year":"2025","journal-title":"Diagnostics"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.014_bib0034","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00259-016-3327-3","article-title":"EANM and the EANM Thyroid Committee. Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer","volume":"43","author":"Verburg","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.11.014_bib0035","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00259-016-3495-1","article-title":"Acknowledging gray areas: 2015 vs. 2009 American Thyroid Association differentiated thyroid cancer guidelines on ablating putatively low-intermediate-risk patients","volume":"44","author":"Frangos","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.11.014_bib0036","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1007\/s00259-025-07187-1","article-title":"131I SPECT\/CT provides prognostic information in patients with differentiated thyroid cancer","volume":"52","author":"Heinrich","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.014_bib0037","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.2214\/AJR.08.1218","article-title":"Incremental value of diagnostic 131I SPECT\/CT fusion imaging in the evaluation of differentiated thyroid carcinoma","volume":"191","author":"Wong","year":"2008","journal-title":"AJR Am J Roentgenol"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.11.014_bib0038","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2967\/jnumed.110.075960","article-title":"The effect of posttherapy 131I SPECT\/CT on risk classification and management of patients with differentiated thyroid cancer","volume":"51","author":"Grewal","year":"2010","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.014_bib0039","first-page":"1107","article-title":"Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer","volume":"85","author":"Wang","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.11.014_bib0040","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/cancers13020317","article-title":"18F-FDG-PET\/CT in patients with advanced, radioiodine refractory thyroid cancer treated with Lenvatinib","volume":"13","author":"Ahmaddy","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.014_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12880-024-01525-9","article-title":"Clinico-pathological factors and [18F]FDG PET\/CT metabolic parameters as prognostic markers in radioiodine-refractory differentiated thyroid carcinoma","volume":"24","author":"Phuong","year":"2024","journal-title":"BMC Med Imaging"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.11.014_bib0042","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.diii.2021.04.004","article-title":"PET\/CT in the management of differentiated thyroid cancer","volume":"102","author":"Zampella","year":"2021","journal-title":"Diagn Interv Imaging"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.014_bib0043","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/RLU.0000000000000429","volume":"39","author":"Jois","year":"2014","journal-title":"Clin Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.11.014_bib0044","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s12020-024-03779-3","article-title":"Somatostatin receptor imaging of thyroid tissue and differentiated thyroid cancer using gallium-68-labeled radiotracers-a review of clinical studies","volume":"85","author":"Pishdad","year":"2024","journal-title":"Endocrine"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.11.014_bib0045","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00259-016-3378-5","article-title":"[(68)Ga]DOTATATE PET\/MRI and [(18)F]FDG PET\/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer","volume":"43","author":"Vrachimis","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.014_bib0046","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/RLU.0000000000001454","article-title":"Imaging of prostate-specific membrane antigen expression in metastatic differentiated thyroid cancer using 68Ga-HBED-CC-PSMA PET\/CT","volume":"42","author":"L\u00fctje","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.11.014_bib0047","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1097\/RLU.0000000000003655","article-title":"Prostate-specific membrane antigen expression in patients with differentiated thyroid cancer with thyroglobulin elevation and negative iodine scintigraphy using 68Ga-PSMA-HBED-CC PET\/CT","volume":"46","author":"Verma","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.11.014_bib0048","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.2967\/jnumed.112.105940","article-title":"Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma","volume":"53","author":"Verbeek","year":"2012","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.11.014_bib0049","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1210\/jc.2019-00177","article-title":"Risk stratification in differentiated thyroid cancer: from detection to final follow-up","volume":"104","author":"Tuttle","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.014_bib0050","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3390\/cancers17030425","article-title":"Current and emerging radiotracers and technologies for detection of advanced differentiated thyroid cancer: A narrative review","volume":"17","author":"Pishdad","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2025.11.014_bib0051","first-page":"dgaf530","article-title":"Artificial intelligence applications in thyroid cancer care","author":"Pozdeyev","year":"2025","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825001679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825001679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T05:07:45Z","timestamp":1771218465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299825001679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0001299825001679"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.11.014","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response assessment in advanced differentiated thyroid cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}